We strive to build a leading R&D pharmaceutical company aiming to expand the boundaries of drug discovery.

Due to the socioeconomic burden of cancer and neurological diseases, drugs that improve quality of life of the patients and caregivers with optimal cost/efficacy data are highly required.

Anavex encompasses a "multiple" research program able to develop novel compounds which can be functionally modified into novel drug candidates with best-in-class efficacy that may prevent and/or treat disease initiation/progression based on their unique mode of action.

The company's research program addresses vital unmet medical and public health needs with 11 compelling therapeutic candidates at advanced preclinical phase targeting CNS ( Alzheimer's disease, epilepsy, depression) and oncology (breast, colorectal, lung and prostate cancer). Our future drug development plans target the areas of multiple sclerosis, pain, infectious diseases, inflammation and additional oncology targets.